Advertisement
Case Report|Articles in Press, 100464

ALK-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to small-cell lung cancer: a case report

  • Author Footnotes
    † These authors have contributed equally to this work as co-first authors
    Huihui Li
    Footnotes
    † These authors have contributed equally to this work as co-first authors
    Affiliations
    The Second Clinical Medical College of Wenzhou Medical University, Wenzhou 325035, Zhejiang, China

    Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）， Institute of Basic Medicine and Cancer（IBMC）， Chinese Academy of Sciences， Hangzhou， Zhejiang 310022， China
    Search for articles by this author
  • Author Footnotes
    † These authors have contributed equally to this work as co-first authors
    Tianqi Song
    Footnotes
    † These authors have contributed equally to this work as co-first authors
    Affiliations
    The Second Clinical Medical College of Wenzhou Medical University, Wenzhou 325035, Zhejiang, China

    Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）， Institute of Basic Medicine and Cancer（IBMC）， Chinese Academy of Sciences， Hangzhou， Zhejiang 310022， China
    Search for articles by this author
  • Xiaoling Xu
    Correspondence
    Correspondence to: Xiaoling Xu, Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences, （Zhejiang Cancer Hospital）， Institute of Basic Medicine and Cancer（IBMC）， Chinese Academy of Sciences， Hangzhou， Zhejiang 310022， China.
    Affiliations
    Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）， Institute of Basic Medicine and Cancer（IBMC）， Chinese Academy of Sciences， Hangzhou， Zhejiang 310022， China

    The Second Clinical Medical College of Wenzhou Medical University, Wenzhou 325035, Zhejiang, China
    Search for articles by this author
  • Author Footnotes
    † These authors have contributed equally to this work as co-first authors
Open AccessPublished:January 19, 2023DOI:https://doi.org/10.1016/j.jtocrr.2023.100464
ALK-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to small-cell lung cancer: a case report
Previous ArticleThe EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations
Next ArticleMassive thymic hyperplasia masquerading as cancer: A case report and review of the literature
      This paper is only available as a PDF. To read, Please Download here.

      Abstract:

      Small cell lung cancer (SCLC) transformation is a phenomenon that is rarely described in anaplastic lymphoma kinase (ALK)-rearranged cancers after treatment with ALK-tyrosine kinase inhibitors (TKIs); however, it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response (PR) after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution based on next-generation sequencing, which may predict small-cell transformation and facilitate early treatment.

      Key words

      Article info

      Publication history

      Accepted: January 17, 2023
      Received in revised form: January 13, 2023
      Received: October 11, 2022

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Credit Statement

      Huihui Li: Conceptualization; Data curation; Formal analysis; Visualization; Software; Roles/Writing - original draft.

      Tianqi Song: Investigation; Data curation; Formal analysis; Methodology; Visualization; Software; Validation.

      Xiaoling Xu: Funding acquisition; Project administration; Resources; Supervision; Writing - review & editing.

      Identification

      DOI: https://doi.org/10.1016/j.jtocrr.2023.100464

      Copyright

      © 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX